- Details
- Dr. May Sadik presents data from the SNMMI meeting highlighting a retrospective study in 45 patients with hormone naïve prostate cancer. The objective was to develop a completely automated method to quantify prostate gland update of 18F-choline in PET/CT images. The hope is that these preliminary data will lead to a better understanding of the relationship between this measure, the clinical data a...
|
- Details
- Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...
|
- Details
- Ur Metser a study that was conducted to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. Biography: Ur Metser, MD, FRCPC, Joint Department of Medical Imaging, the University of Toronto Related Content: 18F-Fluorocholine PET Whole-Bo...
|
- Details
- Claudia Zacharias presents Gallium 6 PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using 68 Ga-PSMA-11 PET/MR. She reviews the potential role of 68 Ga-PSM...
|
- Details
- The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an in...
|
- Details
- Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biographies: Michael Hofman, MBBS (Hon...
|
- Details
- (Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...
|
- Details
- (Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...
|
- Details
- (Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...
|
- Details
- (Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...
|
